Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

BMS takes over antibody platform company Medarex for $2bn

Executive Summary

In its first major acquisition since losing its bid for ImClone to Lilly in October 2008, Bristol-Myers Squibb is gaining full ownership of public antibody drug discovery company Medarex for approximately $2bn in cash.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Partial Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register